Immunotherapy improved blood sugar control in diabetic mice
An immunization experiment in mice modeling accelerated diabetes reduced weight gain and improved glucose tolerance, but how it worked remained unclear.
Limit: The study did not distinguish senescent-cell removal from altered cell behavior
Edited by Boris Djordjevic · AgingResearch.News
In mice with experimentally accelerated diabetes, an immunization experiment improved blood sugar control and reduced markers of senescence, a state in which cells permanently stop dividing. Researchers created the model using a high-fat diet and the drugs dexamethasone and streptozotocin. The immunotherapy targeted IAPE, an endogenous retrovirus—an inherited viral DNA sequence.
Immunized mice mounted stronger immune responses to IAPE. They gained less weight and showed improved fasting insulin and glucose regulation. They also handled an oral glucose dose better. The researchers found reduced senescence markers in pancreatic islets, clusters of hormone-producing cells, alongside a slight decrease in islet IAPE. The authors suggested that targeting endogenous retroviruses may improve metabolic measures through effects on senescent cells.
Why it matters
Senescence is relevant to aging and may contribute to metabolic decline. The work raises the question of whether inherited viral sequences could provide immune targets for addressing that decline.
Caveats
The mechanism remained undefined, including whether the immunotherapy removed senescent cells or changed their behavior. These results came from an accelerated mouse diabetes model and do not establish benefits in people.
The paper
University of Copenhagen
Molecular Metabolism, Oct 29, 2026